I am studying mechanisms of cell death escape by liver cancer cells as a consequence of oncogenic mutations and/or metabolic reprogramming. I obtained a Bachelor of Science in Molecular Biology, a Master of Science in Biomedical Sciences and a PhD in Experimental Oncology from University of Torino, Italy. After training as a visiting graduate student first and postdoctoral research fellow at the Cleveland Clinic and University of California San Diego, I joined Jecure Therapeutics as a research scientist for three years.

Dr. De Giorgi received his PhD in Medical Sciences from the Medical University of Gdansk in Poland, in partnership with the University of Milano-Bicocca in Italy. He performed his postdoctoral studies in lipid metabolism and gene therapy at Baylor College of Medicine in Houston, where he is currently an Assistant Professor.

Rena K. Fox, MD, FACP is Professor of Clinical Medicine at the University of California, San Francisco (UCSF) and an internationally recognized investigator whose work has advanced the integration of hepatology into primary care. Her research spans viral hepatitis, MASLD/MASH, cirrhosis, and hepatocellular carcinoma, with a particular emphasis on implementation science and population health approaches to liver disease.

Dr. Meagan Gray is as Associate Professor of Medicine at the University of Alabama at Birmingham. She founded and directs the MASLD clinic and is the Program Director for the Transplant Hepatology Fellowship Program. Her interests lie in obesity, nutrition, and healthcare disparities for patients living with MASLD.

I am a molecular and vascular biologist specialized in the liver heterogeneity, I have a broad background in biology and bioinformatic analysis that allow me studing the molecular mechanisms controlling the vascular fate and its influence on organ homeostasis. My research focuses on understanding the molecular mechanisms regulating endothelial cell signature and adaptability to expand the "Vascular Medicine" field. The ovearching goal of my laboratory is to develop novel strategies to heal the liver throught recovering the regenerative function of its blood vessels.

Dr. Brown is a professor of Medicine at Wayne State University and Michigan State University. She is the past Medical Director of Liver Transplantation and Chief of the Division of Gastroenterology and Hepatology at Henry Ford Health. She is currently the Medical Director of Transplant Outreach Services and Associate Medical Director of the Henry Ford Transplant Institute. She is the current Chair of the AASLD Foundation Board and past Secretary of AASLD.

Mandana Khalili, MD, MAS is a Professor of Medicine at University of California San Francisco (UCSF) and the Director of Clinical and Translational Research in Hepatology and Chief of Clinical Hepatology at UCSF/San Francisco General Hospital. Her research focuses on addressing epidemiology, systemic complications and outcomes, novel therapies, and health policy related to viral hepatitis, steatotic liver disease (metabolic dysfunction-associated and alcohol related), cirrhosis and liver cancer.

I am a practicing transplant hepatologist and gastroenterologist with interests in clinical informatics and using technology to augment healthcare and health education, the promotion of health equity amongst learners and patients. I also have a special interest in liver diseases in pregnancy and women's liver health.